Research & Development Solution Center
-
Singapore Reduces Risks To Life Sciences Entering The Asian Market
12/28/2012
There are many risks involved with opening pharmaceutical manufacturing operations in Asia, but Signapore has become ideal for the Life Sciences industry.
-
The Rise Of Precompetitive Collaboration
11/29/2012
How biopharmaceutical firms are using precompetitive agreements to exercise economies of scale to the industry in the early stage.
-
Crowdfunding In Life Sciences: A New Route To Finance
11/29/2012
It’s currently hard to get funding, especially if the company is too small or too early to interest investor, that’s why crowdfunding may be the answer.
-
When It Comes To Outsourcing Relationships, Essential Qualities Vary
10/31/2012
Nice Insight’s survey asked outsourcing buyers to separate the essential qualities of an outsourcing relationship from the nonessential, and the essential qualities varied by the buyer category and business size.
-
Evolution In The Research Used For The CMO Awards
10/1/2012
Nice Insights remains focused on CMOs’ and the outsourcing industry but now they will provide more in-depth information about each profiled company with greater segmentation options.
-
In Pharma-Academia Partnerships, Who Will Lead?
9/28/2012
The rise in popularity of the “open innovation” model had led both pharmaceutical companies and academic medical centers to view partnering as a win-win opportunity.
-
Ask The Board October 2012
9/12/2012
What type of economic incentives would you propose to spur antimicrobial drug development?
-
Rediscovering Generics - Sandoz Vows To Serve Patients First
8/30/2012
How Sandoz found a pathway back to relative prosperity and purpose, with a detailed and instructive account that can be useful to an executive charged with a similar challenge.
-
Not-For-Profits Fill The R&D Gap For Underserved Diseases
8/1/2012
Nonprofit advocacy groups to support R&D in diseases where big pharma cannot, the advocacy groups seek product not profit, focusing efforts on translational research and bringing cures to the market. By Fred Olds, contributing editor
-
Why Life Sciences Needs To Reassess Their U.S. Patent Strategies
8/1/2012
Life sciences companies now need to reassess and adapt their U.S. patent strategies. The rules are dramatically changing, particularly with regard to the AIA’s provisions concerning novelty and prior art.